Ranking JAK2 Inhibitor Competition: Ajax's Type II Approach Against Incumbent Type I Therapies

Ajax Therapeutics' AJ1-11095 is entering the myelofibrosis market with a fundamentally different approach from currently approved JAK2 inhibitors. It is the first JAK2 inhibitor to enter clinical development that binds the Type II conformation of JAK2, whereas all currently approved JAK2 inhibitors bind the Type I conformation. Lilly completed its acquisition of Ajax in 2026, bringing the program into its oncology pipeline.

Jakafi Represents the Established Model

The incumbent benchmark is Jakafi (ruxolitinib) from Incyte, a Type I JAK2 inhibitor that has become an established treatment for myelofibrosis. Type I inhibitors can reduce spleen enlargement and improve symptoms, but treatment response can diminish over time. Ajax is specifically developing AJ1-11095 for patients who have previously received a Type I JAK2 inhibitor and either failed to respond or lost response.

Why Type II Binding Matters

The competitive distinction comes from how the medicines interact with JAK2. Type I inhibitors bind the kinase's active conformation, while AJ1-11095 selectively binds its inactive Type II conformation. Ajax's preclinical research showed that AJ1-11095 could restore JAK/STAT pathway inhibition in cells that had persisted under ruxolitinib treatment, while also reducing mutant allele burden and bone-marrow fibrosis in experimental models.

The Real Target Is Treatment Resistance

This means AJ1-11095 is not simply trying to replace Jakafi in the existing treatment market. Its initial clinical positioning is more targeted: patients whose disease has become refractory to a Type I JAK2 inhibitor. That creates a potentially important second-line opportunity because loss of response remains a major challenge in myelofibrosis treatment. Ajax has described the program as a potential option for patients who become resistant to existing Type I therapies.

Early Clinical Data Strengthen the Case

The competitive thesis moved beyond laboratory research in 2026 when initial Phase 1 data from AJX-101 showed an encouraging safety profile and promising clinical activity in patients with myelofibrosis who had previously failed a Type I JAK2 inhibitor. Lilly presented the data at the 2026 European Hematology Association meeting, giving the program its first clinical proof-of-concept signal. However, the evidence remains early-stage and does not yet establish superiority over approved treatments.

Lilly Adds Significant Commercial Firepower

Lilly's acquisition could substantially strengthen the program's competitive position. As the new owner, Lilly brings global clinical-development, regulatory and commercial capabilities to AJ1-11095. The company has also indicated that the drug could potentially move beyond the previously treated population and eventually be developed for both first- and second-line settings if later clinical data support that strategy.

The Competitive Ranking

AJ1-11095 therefore ranks as a potentially disruptive rather than yet proven competitor to Type I JAK2 therapies. Jakafi and other established inhibitors have the advantage of years of clinical use and commercial experience, while Ajax's Type II mechanism offers a differentiated strategy aimed particularly at resistance and deeper disease control. The decisive benchmark will be whether Phase 2 and later-stage trials demonstrate that this mechanistic advantage translates into durable clinical benefits for patients.